Khosla Impact, established in 2013, is an impact investment firm based in Menlo Park, California. It focuses on assisting high-impact entrepreneurs who develop products and services for the three billion people at the bottom of the world's economic pyramid. The firm invests in for-profit enterprises serving low-income individuals and small businesses in emerging markets, with a primary focus on South Asia. Khosla Impact encourages experimentation and supports entrepreneurs passionate about solving socio-economic challenges through technology and innovative business models.
Cyberhaven, Inc., established in 2014 and headquartered in Boston, Massachusetts, specializes in enterprise cybersecurity. The company's core offering is a Data Detection and Response platform designed to safeguard intellectual property from theft and insider threats. This platform assesses internal actions across an organization, identifying risky behaviors before they result in a breach. It provides full-context data tracing to minimize false positives and negatives, and accelerates incident response investigations, enabling clients to protect their data efficiently. Cyberhaven's technology covers the protection of sensitive documents across various platforms, including Office 365, on-premise SharePoint, and Google Apps. The company operates globally with additional offices in Palo Alto, California; Lausanne, Switzerland; and Kiev, Ukraine.
Regie.ai
Series B in 2025
Regie.ai is a developer of an AI-powered platform that focuses on enhancing sales engagement and automating outbound prospecting. Its product, RegieOne, combines various functionalities such as sales engagement, parallel dialing, data enrichment, and intent analysis, allowing operations teams to manage their processes efficiently from a centralized interface. Additionally, Regie.ai's platform facilitates the creation, testing, and analysis of personalized sales campaigns, thereby improving engagement and optimizing the performance of frontline sales teams. Through its innovative approach, Regie.ai aims to streamline sales workflows and drive better outcomes for businesses.
C the Signs
Venture Round in 2025
C the Signs is a cancer prediction system that empowers general practitioners to identify patients at risk of cancer in its early and treatable stages. The platform provides an easy-to-use format for simultaneously checking combinations of signs, symptoms, and risk factors during patient consultations, when decision-making capabilities are most impactful. By analyzing various clinical data points, C the Signs aids physicians in recommending necessary investigations or urgent referrals in under 30 seconds, thereby facilitating timely diagnosis and treatment. The company's mission is to enhance patient outcomes by fast-tracking individuals to appropriate tests or referrals, ultimately aiming to reduce cancer-related mortality rates.
Clear Labs
Series D in 2025
Clear Labs, Inc. is a food analytics company based in Menlo Park, California, founded in 2013. The company specializes in providing a comprehensive analytics platform that analyzes the molecular contents of food and ingredients. Its offerings include Clear Dx™ and Clear Safety™, which utilize next-generation sequencing and data analytics for food safety testing and infectious disease surveillance. Clear Labs serves food manufacturers, suppliers, and retailers by ensuring transparency throughout the supply chain and testing products for various factors such as authenticity, contamination, allergens, and nutritional content. The platform delivers actionable insights that enhance safety and operational efficiency while supporting public health initiatives. Through its integrated genomics system, Clear Labs aims to simplify complex diagnostics across clinical and applied markets, making genomic insights accessible to labs, hospitals, and businesses.
Jones
Series B in 2025
The Jones Agency, Inc. is a liability insurance underwriting company that specializes in serving general construction and property management contractors. Founded in 2016 and based in New York, it provides insurance solutions tailored for various professions, including contractors, electricians, HVAC technicians, and landscapers. In addition to its underwriting services, Jones offers a software platform designed to streamline liability management for real estate companies, addressing the complexities of insurance compliance. This innovative approach aims to simplify the traditionally cumbersome process of managing insurance certificates for owners, managers, and developers within the commercial real estate sector. Through its services, Jones seeks to enhance efficiency and effectiveness in insurance management for its clients.
Distyl
Series A in 2024
Distyl AI specializes in helping organizations enhance their readiness for artificial intelligence by developing customized AI solutions that align with their specific data, workflows, and workforce needs. The company offers a generative AI solutions platform that supports major institutions in adopting foundational models and preparing for AI integration. By collaborating with leading organizations globally, Distyl AI aims to create reliable and seamlessly integrated AI-driven services, enabling enterprises to thrive in an increasingly AI-assisted economy.
Profound
Seed Round in 2024
Profound offers cutting-edge technology that analyzes how AI platforms portray and discuss brands, assisting businesses in managing their online reputation. The platform enables companies to oversee and comprehend their brand's representation in AI-generated responses, ensuring a favorable image. Profound functions as a robust analytics tool tailored for enterprise brands, aimed at improving their visibility and effectiveness in AI search environments.
Q Bio
Venture Round in 2024
Q Bio, Inc., established in 2015, develops a comprehensive health assessment platform that combines advanced non-invasive imaging, genetic testing, vital signs, and medical history to provide a snapshot of an individual's health. The company's flagship product, Q BioVault, aggregates and summarizes an individual's entire medical history, identifying and tracking significant health changes. Q Bio's interdisciplinary team, based in San Carlos, California, comprises experts in fields such as applied math, computational physics, electrical engineering, genetics, and radiology. Backed by prominent venture capital firms, the company aims to empower healthcare professionals with proactive, data-driven insights to improve patient outcomes.
Cyberhaven
Series C in 2024
Cyberhaven, Inc., established in 2014 and headquartered in Boston, Massachusetts, specializes in enterprise cybersecurity. The company's core offering is a Data Detection and Response platform designed to safeguard intellectual property from theft and insider threats. This platform assesses internal actions across an organization, identifying risky behaviors before they result in a breach. It provides full-context data tracing to minimize false positives and negatives, and accelerates incident response investigations, enabling clients to protect their data efficiently. Cyberhaven's technology covers the protection of sensitive documents across various platforms, including Office 365, on-premise SharePoint, and Google Apps. The company operates globally with additional offices in Palo Alto, California; Lausanne, Switzerland; and Kiev, Ukraine.
Sword Health
Secondary Market in 2024
Sword Health is a digital health company specializing in physical rehabilitation. It employs artificial intelligence to deliver personalized care to patients worldwide, anytime, anywhere. The platform offers interactive exercise routines supervised by remote physiotherapists, aiming to reduce costs and improve accessibility to physical therapy. Clinicians can utilize the data collected to enhance decision-making processes.
Nabla Bio
Series A in 2024
Nabla Bio operates an autoreverse platform that facilitates the rapid discovery of novel protein variants with unique properties. By leveraging insights gained from billions of natural proteins, the company engineers these enhanced proteins for both medical and industrial applications. Through extensive experimentation, Nabla Bio develops new medicines and improves nutritional products, allowing clients to conduct complex measurements of protein function and implement innovative solutions in various fields.
Symbolica AI
Series A in 2024
Symbolica AI is a research-driven company that develops a unique business model platform. This platform leverages geometric and topological principles in machine learning to train models using formal computational logic, rather than traditional statistical methods. The result is enhanced decision-making capabilities for clients, fostering business growth.
Moonwalk Biosciences
Series A in 2024
Moonwalk Biosciences is a genomic medicine startup focused on developing precision epigenetic therapeutics. The company is creating a profiling and engineering technology platform that leverages advanced artificial intelligence to deliver an in-depth understanding of the epigenome in both health and disease. This innovative approach allows healthcare providers to explore new avenues for therapy discovery and facilitates the reprogramming of cells to restore their healthy state. By integrating AI-driven insights, Moonwalk Biosciences aims to transform the landscape of therapeutic development and improve patient outcomes.
Coframe
Seed Round in 2023
Coframe is a technology company that specializes in AI-driven A/B testing and personalization for websites and applications. Its platform continuously analyzes user interactions to optimize content, improving user experience, engagement, and conversion rates. Coframe's solution involves training multimodal models to understand user behavior and business goals, enabling user interfaces to autonomously enhance themselves over time.
Arkifi
Seed Round in 2023
Arkifi is an AI company specializing in creating financial analyst tools. Its core product is an AI framework that generates accurate, reliable results, minimizing the risk of factual errors often associated with generative AI. This allows financial professionals to enhance their workflow efficiency and make decisions with confidence.
Advocate
Seed Round in 2023
Advocate is a company that focuses on enhancing interactions between government agencies and civilians through the development of AI applications. Its platform automates filing and response processes, aiming to improve efficiency and effectiveness in managing federal government benefits programs. By streamlining human processing, decision-making, and risk assessment, Advocate seeks to create a more transparent and accessible experience for disabled Americans in accessing government benefits. The company emphasizes that the application process should be straightforward, ensuring that qualified individuals can easily obtain the financial support they need.
Gather Health
Series A in 2023
Gather Health is an international healthcare technology company dedicated to empowering patients with chronic diseases to enhance their health. The company specializes in mobile and cloud-based healthcare applications that utilize the latest medical and behavioral change research to motivate and educate patients. By connecting physicians, patients, their families, and patient communities, Gather Health aims to provide continuous and holistic care, ultimately improving health outcomes. The rise in chronic diseases, such as obesity and diabetes, has created a demand for better care, which Gather Health addresses by equipping patients and healthcare providers with effective tools for managing these conditions. Their flagship product, the Gather Health Diabetes platform, has been successfully implemented in cities including Mumbai, Ahmedabad, Hyderabad, Chennai, and Bangalore, showing positive health outcomes for patients and increased efficiency for healthcare providers. Headquartered in Hong Kong, with offices in Beijing, New York, and India, Gather Health's team comprises clinicians, health experts, interaction designers, and engineers experienced in global healthcare.
Regie.ai
Series A in 2023
Regie.ai is a developer of an AI-powered platform that focuses on enhancing sales engagement and automating outbound prospecting. Its product, RegieOne, combines various functionalities such as sales engagement, parallel dialing, data enrichment, and intent analysis, allowing operations teams to manage their processes efficiently from a centralized interface. Additionally, Regie.ai's platform facilitates the creation, testing, and analysis of personalized sales campaigns, thereby improving engagement and optimizing the performance of frontline sales teams. Through its innovative approach, Regie.ai aims to streamline sales workflows and drive better outcomes for businesses.
Mirvie
Series B in 2022
Mirvie is a biotech company focused on developing non-invasive tests aimed at improving maternal-fetal health. Founded in 2018 and based in South San Francisco, California, Mirvie offers a medical diagnostic platform that provides actionable insights for mothers and families throughout their pregnancy journey. The company's innovative predictive tests help medical practitioners identify at-risk pregnancies, allowing for timely interventions and enhanced management of pregnancy-related concerns. By prioritizing safety and health, Mirvie seeks to empower families with the information necessary for better pregnancy outcomes.
Loop
Series B in 2022
Loop Health is a healthcare provider based in Pune, India, founded in 2018. The company offers a range of services including acute and urgent care, chronic condition management, women's health, health coaching, and preventive care. Loop Health aims to simplify the healthcare experience by connecting patients with family physicians, specialists, and hospitals, facilitating access to major medical treatments. Their team of Loop Coordinators assists patients in finding appropriate doctors, comparing treatment costs, obtaining second opinions, and managing admission procedures, thereby alleviating the stress associated with healthcare decisions. Additionally, Loop Health features a virtual medical practice that supports employees and their families, allowing them to consult with healthcare experts and medical advisors without delay, ultimately promoting better health management and cost-effectiveness.
Myko
Seed Round in 2022
Myko AI is an artificial intelligence tool that pulls financial data from spreadsheets and helps make successful revenue-generating decisions with minimum onboarding. The company's application integrates directly into users' existing CRM platforms and chat applications, allowing data to be analyzed in seconds. This enables businesses to drive more revenue by providing their teams with deeper analytical capabilities and improving the financial reporting process by spending less time copying and pasting data.
Scipher Medicine
Series D in 2022
Scipher Medicine Corporation is a biotechnology company based in Waltham, Massachusetts, that specializes in precision medicine for patients with autoimmune and cardiovascular diseases. The company has developed a molecular technology platform that utilizes blood samples to analyze RNA and predict patient responses to drug therapies. Its primary offerings include PrismDx tests, which identify patients who may not respond to certain medications, ensuring they can be prescribed alternative treatments. Notably, the PrismRA test assesses patients with rheumatoid arthritis to determine their likelihood of responding to anti-TNF therapies, while PrismUC serves a similar purpose for patients with ulcerative colitis. By focusing on the underlying disease biology rather than just symptoms, Scipher Medicine aims to optimize treatment from the outset, potentially reducing the healthcare costs associated with ineffective therapies. Established in 2013 and rebranded in 2015, Scipher Medicine is committed to transforming drug prescription practices and advancing drug development through its innovative approach.
Nabla Bio
Seed Round in 2021
Nabla Bio operates an autoreverse platform that facilitates the rapid discovery of novel protein variants with unique properties. By leveraging insights gained from billions of natural proteins, the company engineers these enhanced proteins for both medical and industrial applications. Through extensive experimentation, Nabla Bio develops new medicines and improves nutritional products, allowing clients to conduct complex measurements of protein function and implement innovative solutions in various fields.
Sword Health
Series D in 2021
Sword Health is a digital health company specializing in physical rehabilitation. It employs artificial intelligence to deliver personalized care to patients worldwide, anytime, anywhere. The platform offers interactive exercise routines supervised by remote physiotherapists, aiming to reduce costs and improve accessibility to physical therapy. Clinicians can utilize the data collected to enhance decision-making processes.
Loop
Series A in 2021
Loop Health is a healthcare provider based in Pune, India, founded in 2018. The company offers a range of services including acute and urgent care, chronic condition management, women's health, health coaching, and preventive care. Loop Health aims to simplify the healthcare experience by connecting patients with family physicians, specialists, and hospitals, facilitating access to major medical treatments. Their team of Loop Coordinators assists patients in finding appropriate doctors, comparing treatment costs, obtaining second opinions, and managing admission procedures, thereby alleviating the stress associated with healthcare decisions. Additionally, Loop Health features a virtual medical practice that supports employees and their families, allowing them to consult with healthcare experts and medical advisors without delay, ultimately promoting better health management and cost-effectiveness.
NetSpring
Series A in 2021
NetSpring specializes in product and customer journey analytics, providing a platform that enables businesses to gain insights into product usage and user behavior across multiple channels. Their tools facilitate the analysis of customer experiences without the need for data duplication, allowing for warehouse-native analytics that cater to modern data environments. By empowering product, growth, and data teams, NetSpring helps organizations prioritize feature development, enhance customer acquisition strategies, and minimize churn through a deeper understanding of user interaction trends.
Jones
Series A in 2021
The Jones Agency, Inc. is a liability insurance underwriting company that specializes in serving general construction and property management contractors. Founded in 2016 and based in New York, it provides insurance solutions tailored for various professions, including contractors, electricians, HVAC technicians, and landscapers. In addition to its underwriting services, Jones offers a software platform designed to streamline liability management for real estate companies, addressing the complexities of insurance compliance. This innovative approach aims to simplify the traditionally cumbersome process of managing insurance certificates for owners, managers, and developers within the commercial real estate sector. Through its services, Jones seeks to enhance efficiency and effectiveness in insurance management for its clients.
Sword Health
Series C in 2021
Sword Health is a digital health company specializing in physical rehabilitation. It employs artificial intelligence to deliver personalized care to patients worldwide, anytime, anywhere. The platform offers interactive exercise routines supervised by remote physiotherapists, aiming to reduce costs and improve accessibility to physical therapy. Clinicians can utilize the data collected to enhance decision-making processes.
Ellipsis Health
Series A in 2021
Ellipsis Health, Inc. is a technology company based in San Francisco, California, founded in 2013. It specializes in developing analytics solutions that utilize artificial intelligence to enhance behavioral health assessments by analyzing patient speech and clinical data. The company's platform offers a behavioral biomarker technology that generates clinical-grade evaluations of anxiety and depression severity, as well as sub-clinical assessments of stress. This innovative approach allows healthcare systems to continuously monitor their patient populations for mental health conditions, particularly depression, and facilitates timely support for patients in need. By integrating affective computing into patient and care team interactions, Ellipsis Health aims to create real-time behavioral health vital signs for improved patient outcomes.
Clear Labs
Series C in 2021
Clear Labs, Inc. is a food analytics company based in Menlo Park, California, founded in 2013. The company specializes in providing a comprehensive analytics platform that analyzes the molecular contents of food and ingredients. Its offerings include Clear Dx™ and Clear Safety™, which utilize next-generation sequencing and data analytics for food safety testing and infectious disease surveillance. Clear Labs serves food manufacturers, suppliers, and retailers by ensuring transparency throughout the supply chain and testing products for various factors such as authenticity, contamination, allergens, and nutritional content. The platform delivers actionable insights that enhance safety and operational efficiency while supporting public health initiatives. Through its integrated genomics system, Clear Labs aims to simplify complex diagnostics across clinical and applied markets, making genomic insights accessible to labs, hospitals, and businesses.
Scipher Medicine
Series C in 2021
Scipher Medicine Corporation is a biotechnology company based in Waltham, Massachusetts, that specializes in precision medicine for patients with autoimmune and cardiovascular diseases. The company has developed a molecular technology platform that utilizes blood samples to analyze RNA and predict patient responses to drug therapies. Its primary offerings include PrismDx tests, which identify patients who may not respond to certain medications, ensuring they can be prescribed alternative treatments. Notably, the PrismRA test assesses patients with rheumatoid arthritis to determine their likelihood of responding to anti-TNF therapies, while PrismUC serves a similar purpose for patients with ulcerative colitis. By focusing on the underlying disease biology rather than just symptoms, Scipher Medicine aims to optimize treatment from the outset, potentially reducing the healthcare costs associated with ineffective therapies. Established in 2013 and rebranded in 2015, Scipher Medicine is committed to transforming drug prescription practices and advancing drug development through its innovative approach.
Sword Health
Series B in 2021
Sword Health is a digital health company specializing in physical rehabilitation. It employs artificial intelligence to deliver personalized care to patients worldwide, anytime, anywhere. The platform offers interactive exercise routines supervised by remote physiotherapists, aiming to reduce costs and improve accessibility to physical therapy. Clinicians can utilize the data collected to enhance decision-making processes.
Lumiata
Series B in 2021
Lumiata Inc. specializes in predictive health analytics tailored for risk-bearing organizations, including hospital networks and insurance carriers. Founded in 2013 and based in San Mateo, California, the company has developed a medical graph that organizes and analyzes diverse healthcare data, enabling real-time predictive analytics. Its flagship product, The Lumiata Risk Matrix, provides personalized predictions regarding individual health changes, supported by a chain of medical reasoning. By leveraging over 120 million patient records and proprietary clinical knowledge, Lumiata's machine learning tools empower healthcare providers and payers to enhance decision-making, manage costs, and improve patient care. The company serves a range of clients, including payers, population health organizations, and digital health companies, facilitating applications in underwriting and care management while prioritizing member privacy.
Invoy
Series A in 2020
Invoy is a company focused on providing personalized nutrition and wellness services through innovative monitoring medical devices. By utilizing science, data, and artificial intelligence, Invoy's technology captures real-time data on individual metabolism, allowing for tailored nutritional recommendations. The company aims to enhance individual health and weight loss goals by addressing the unique body chemistry of each person. With an emphasis on affordability, Invoy offers breath analyzers for medical applications, enabling users to effectively monitor their health and optimize their wellness journey.
Siren
Series B in 2020
Siren Care, Inc. is a health technology company based in San Francisco, California, founded in 2015. It specializes in wearable devices designed for diabetic health tracking, particularly through its flagship product, the Siren diabetic socks. These smart socks continuously monitor foot temperature, providing crucial data that can help detect early signs of diabetic ulcers, thereby reducing the risk of amputations. The temperature data is transmitted via an application, allowing healthcare providers to monitor patients effectively and intervene early if necessary. Siren Care aims to enhance healthcare for individuals with chronic diseases by collaborating with both providers and payers to improve patient outcomes in diabetic foot care.
Clear Labs
Venture Round in 2020
Clear Labs, Inc. is a food analytics company based in Menlo Park, California, founded in 2013. The company specializes in providing a comprehensive analytics platform that analyzes the molecular contents of food and ingredients. Its offerings include Clear Dx™ and Clear Safety™, which utilize next-generation sequencing and data analytics for food safety testing and infectious disease surveillance. Clear Labs serves food manufacturers, suppliers, and retailers by ensuring transparency throughout the supply chain and testing products for various factors such as authenticity, contamination, allergens, and nutritional content. The platform delivers actionable insights that enhance safety and operational efficiency while supporting public health initiatives. Through its integrated genomics system, Clear Labs aims to simplify complex diagnostics across clinical and applied markets, making genomic insights accessible to labs, hospitals, and businesses.
Sword Health
Series A in 2020
Sword Health is a digital health company specializing in physical rehabilitation. It employs artificial intelligence to deliver personalized care to patients worldwide, anytime, anywhere. The platform offers interactive exercise routines supervised by remote physiotherapists, aiming to reduce costs and improve accessibility to physical therapy. Clinicians can utilize the data collected to enhance decision-making processes.
Q Bio
Series B in 2020
Q Bio, Inc., established in 2015, develops a comprehensive health assessment platform that combines advanced non-invasive imaging, genetic testing, vital signs, and medical history to provide a snapshot of an individual's health. The company's flagship product, Q BioVault, aggregates and summarizes an individual's entire medical history, identifying and tracking significant health changes. Q Bio's interdisciplinary team, based in San Carlos, California, comprises experts in fields such as applied math, computational physics, electrical engineering, genetics, and radiology. Backed by prominent venture capital firms, the company aims to empower healthcare professionals with proactive, data-driven insights to improve patient outcomes.
NetSpring
Seed Round in 2019
NetSpring specializes in product and customer journey analytics, providing a platform that enables businesses to gain insights into product usage and user behavior across multiple channels. Their tools facilitate the analysis of customer experiences without the need for data duplication, allowing for warehouse-native analytics that cater to modern data environments. By empowering product, growth, and data teams, NetSpring helps organizations prioritize feature development, enhance customer acquisition strategies, and minimize churn through a deeper understanding of user interaction trends.
Sword Health
Series A in 2019
Sword Health is a digital health company specializing in physical rehabilitation. It employs artificial intelligence to deliver personalized care to patients worldwide, anytime, anywhere. The platform offers interactive exercise routines supervised by remote physiotherapists, aiming to reduce costs and improve accessibility to physical therapy. Clinicians can utilize the data collected to enhance decision-making processes.
BioAge Labs
Series B in 2019
BioAge Labs, Inc. is a biotechnology company focused on developing therapies to address aging and age-related diseases. The company utilizes a systems biology and artificial intelligence platform to identify key drug targets that influence aging and analyze extensive datasets to uncover the molecular drivers of age-related conditions. BioAge Labs is advancing several drug candidates, including BGE-117, a hypoxia-inducible factor prolyl hydroxylase inhibitor designed to activate genes involved in critical biological processes such as tissue regeneration and vascular remodeling. Additionally, BGE-175, an orally administered inhibitor of the prostaglandin D2 DP1 signaling pathway, aims to mitigate risks associated with immune aging and respiratory infections. Founded in 2015 and based in Richmond, California, BioAge Labs is committed to discovering and developing innovative treatments that harness the biology of human aging.
Siren
Series A in 2018
Siren Care, Inc. is a health technology company based in San Francisco, California, founded in 2015. It specializes in wearable devices designed for diabetic health tracking, particularly through its flagship product, the Siren diabetic socks. These smart socks continuously monitor foot temperature, providing crucial data that can help detect early signs of diabetic ulcers, thereby reducing the risk of amputations. The temperature data is transmitted via an application, allowing healthcare providers to monitor patients effectively and intervene early if necessary. Siren Care aims to enhance healthcare for individuals with chronic diseases by collaborating with both providers and payers to improve patient outcomes in diabetic foot care.
Clear Labs
Series B in 2018
Clear Labs, Inc. is a food analytics company based in Menlo Park, California, founded in 2013. The company specializes in providing a comprehensive analytics platform that analyzes the molecular contents of food and ingredients. Its offerings include Clear Dx™ and Clear Safety™, which utilize next-generation sequencing and data analytics for food safety testing and infectious disease surveillance. Clear Labs serves food manufacturers, suppliers, and retailers by ensuring transparency throughout the supply chain and testing products for various factors such as authenticity, contamination, allergens, and nutritional content. The platform delivers actionable insights that enhance safety and operational efficiency while supporting public health initiatives. Through its integrated genomics system, Clear Labs aims to simplify complex diagnostics across clinical and applied markets, making genomic insights accessible to labs, hospitals, and businesses.
Pymetrics
Series B in 2018
Pymetrics, Inc. is a company that specializes in developing neuroscience-based assessment and prediction technology aimed at transforming the recruitment, retention, and development of employees. Founded in 2013 and headquartered in New York City, Pymetrics utilizes a combination of neuroscience and machine learning to create a talent matching platform. This platform collects behavioral data from successful professionals across various roles to identify key traits that distinguish top performers from the general population. By offering cognitive and emotional assessment solutions, along with a personalized recommendation engine, Pymetrics enhances the effectiveness and accuracy of the hiring process, while promoting unbiased recruitment practices.
Scipher Medicine
Series A in 2018
Scipher Medicine Corporation is a biotechnology company based in Waltham, Massachusetts, that specializes in precision medicine for patients with autoimmune and cardiovascular diseases. The company has developed a molecular technology platform that utilizes blood samples to analyze RNA and predict patient responses to drug therapies. Its primary offerings include PrismDx tests, which identify patients who may not respond to certain medications, ensuring they can be prescribed alternative treatments. Notably, the PrismRA test assesses patients with rheumatoid arthritis to determine their likelihood of responding to anti-TNF therapies, while PrismUC serves a similar purpose for patients with ulcerative colitis. By focusing on the underlying disease biology rather than just symptoms, Scipher Medicine aims to optimize treatment from the outset, potentially reducing the healthcare costs associated with ineffective therapies. Established in 2013 and rebranded in 2015, Scipher Medicine is committed to transforming drug prescription practices and advancing drug development through its innovative approach.
Remedy
Seed Round in 2018
Remedy is a prescriptive chronic care analytics platform employing artificial intelligence to help value-based health systems determine who should get what care, when, how, and by whom to maximize patient health outcomes per dollar spent. We are a design-driven company with core medical AI technology capable of diagnosing disease, catching hidden high-risk diagnoses, and projecting the development of patient’s health into the future. Built around our core AI engine, our first product Remedy Sentinel helps value-based providers identify hidden chronic, co-morbid conditions and intervene by engaging high-risk patients prior to onset. We envision a world where healthcare marries the science of “health” with the art of “care”: scientific, data-driven decision making drives the best outcomes for each individual patient, and frees providers to focus on applying their human touch. Remedy combines novel artificial intelligence algorithms for predictive medical analytics with a healthcare-optimized product development process to give leaders the tools they need to transform their delivery networks and thrive in a value-based care environment. With this approach, Remedy builds a scalable suite of products that, when deployed, learn from experience, and grow into a solution optimized to fit the needs of specific provider groups and the populations they serve. Remedy systematically maximizes the patient health outcome achieved with each dollar spent by using AI to help determine what care is delivered to whom, when it is delivered, where it is delivered, how it is delivered, followed, and supported, and who should deliver it. We not only surface insights, but also build the necessary tools and helps coordinate step-by-step implementation processes to affect real change.
Lumiata
Series B in 2018
Lumiata Inc. specializes in predictive health analytics tailored for risk-bearing organizations, including hospital networks and insurance carriers. Founded in 2013 and based in San Mateo, California, the company has developed a medical graph that organizes and analyzes diverse healthcare data, enabling real-time predictive analytics. Its flagship product, The Lumiata Risk Matrix, provides personalized predictions regarding individual health changes, supported by a chain of medical reasoning. By leveraging over 120 million patient records and proprietary clinical knowledge, Lumiata's machine learning tools empower healthcare providers and payers to enhance decision-making, manage costs, and improve patient care. The company serves a range of clients, including payers, population health organizations, and digital health companies, facilitating applications in underwriting and care management while prioritizing member privacy.
Siren
Seed Round in 2018
Siren Care, Inc. is a health technology company based in San Francisco, California, founded in 2015. It specializes in wearable devices designed for diabetic health tracking, particularly through its flagship product, the Siren diabetic socks. These smart socks continuously monitor foot temperature, providing crucial data that can help detect early signs of diabetic ulcers, thereby reducing the risk of amputations. The temperature data is transmitted via an application, allowing healthcare providers to monitor patients effectively and intervene early if necessary. Siren Care aims to enhance healthcare for individuals with chronic diseases by collaborating with both providers and payers to improve patient outcomes in diabetic foot care.
Q Bio
Series A in 2018
Q Bio, Inc., established in 2015, develops a comprehensive health assessment platform that combines advanced non-invasive imaging, genetic testing, vital signs, and medical history to provide a snapshot of an individual's health. The company's flagship product, Q BioVault, aggregates and summarizes an individual's entire medical history, identifying and tracking significant health changes. Q Bio's interdisciplinary team, based in San Carlos, California, comprises experts in fields such as applied math, computational physics, electrical engineering, genetics, and radiology. Backed by prominent venture capital firms, the company aims to empower healthcare professionals with proactive, data-driven insights to improve patient outcomes.
DiscernDx
Seed Round in 2018
DiscernDx is a healthcare technology company based in Palo Alto, California, founded in 2017. It operates an online platform that provides users with access to individualized clinical and molecular data, enabling proactive health management and informed decision-making. The platform leverages artificial intelligence and machine learning to detect, measure, and interpret signals from the body, facilitating early disease detection and personalized care. By focusing on the earliest indicators of developing diseases as well as existing conditions, DiscernDx aims to improve health outcomes and transform the healthcare experience for individuals.
Mirvie
Series A in 2018
Mirvie is a biotech company focused on developing non-invasive tests aimed at improving maternal-fetal health. Founded in 2018 and based in South San Francisco, California, Mirvie offers a medical diagnostic platform that provides actionable insights for mothers and families throughout their pregnancy journey. The company's innovative predictive tests help medical practitioners identify at-risk pregnancies, allowing for timely interventions and enhanced management of pregnancy-related concerns. By prioritizing safety and health, Mirvie seeks to empower families with the information necessary for better pregnancy outcomes.
Olive
Series C in 2017
Olive deploys the AI workforce built specifically for healthcare, delivering hospitals and health systems increased revenue, reduced costs, and increased capacity. Olive automates repetitive, high-volume tasks and workflows, monitoring their performance, identifying improvements, and finding opportunities for new work. Olive gives power back to providers through her ever-growing, unparalleled intelligence made up of shared memories, collective wisdom, and global awareness, learning like a network so hospitals never have to solve the same problem twice. Olive was founded in 2012 and is headquartered in Columbus, Ohio.
Ellipsis Health
Seed Round in 2017
Ellipsis Health, Inc. is a technology company based in San Francisco, California, founded in 2013. It specializes in developing analytics solutions that utilize artificial intelligence to enhance behavioral health assessments by analyzing patient speech and clinical data. The company's platform offers a behavioral biomarker technology that generates clinical-grade evaluations of anxiety and depression severity, as well as sub-clinical assessments of stress. This innovative approach allows healthcare systems to continuously monitor their patient populations for mental health conditions, particularly depression, and facilitates timely support for patients in need. By integrating affective computing into patient and care team interactions, Ellipsis Health aims to create real-time behavioral health vital signs for improved patient outcomes.
Lumiata
Series A in 2017
Lumiata Inc. specializes in predictive health analytics tailored for risk-bearing organizations, including hospital networks and insurance carriers. Founded in 2013 and based in San Mateo, California, the company has developed a medical graph that organizes and analyzes diverse healthcare data, enabling real-time predictive analytics. Its flagship product, The Lumiata Risk Matrix, provides personalized predictions regarding individual health changes, supported by a chain of medical reasoning. By leveraging over 120 million patient records and proprietary clinical knowledge, Lumiata's machine learning tools empower healthcare providers and payers to enhance decision-making, manage costs, and improve patient care. The company serves a range of clients, including payers, population health organizations, and digital health companies, facilitating applications in underwriting and care management while prioritizing member privacy.
Catalia Health
Seed Round in 2017
Catalia Health Inc. is a San Francisco-based company that develops a cloud-based patient care management platform aimed at enhancing healthcare delivery. Established in 2014, the company integrates artificial intelligence, psychology, and medicine to improve patient engagement and support. Its platform provides healthcare providers with real-time data on patient progress and challenges, facilitating effective communication through mobile apps, web interfaces, and an interactive robotic coach. By delivering tailored conversations to patients, Catalia Health aims to address ongoing healthcare issues, ultimately enabling healthcare professionals to monitor adherence to treatment and improve overall patient outcomes.
Pymetrics
Series A in 2017
Pymetrics, Inc. is a company that specializes in developing neuroscience-based assessment and prediction technology aimed at transforming the recruitment, retention, and development of employees. Founded in 2013 and headquartered in New York City, Pymetrics utilizes a combination of neuroscience and machine learning to create a talent matching platform. This platform collects behavioral data from successful professionals across various roles to identify key traits that distinguish top performers from the general population. By offering cognitive and emotional assessment solutions, along with a personalized recommendation engine, Pymetrics enhances the effectiveness and accuracy of the hiring process, while promoting unbiased recruitment practices.
Xcalar
Series A in 2017
Xcalar, Inc., founded in 2013 and based in San Jose, California, specializes in data infrastructure services through its innovative analytics platform. This platform facilitates the Fundamental Discovery of significant insights directly from petabytes of raw data, enabling businesses to uncover information that would otherwise remain hidden. Xcalar's technology features a relational scale-out compute architecture that enhances the accessibility and management of big data, streamlining the analysis process. Notably, it employs a patent-pending True Data In Place technology that eliminates the need for data preparation or shuffling, allowing for immediate analysis without data movement. This approach results in significantly faster time-to-insight, making Xcalar's solutions highly efficient for organizations dealing with complex datasets.
Guardant Health
Series E in 2017
Guardant Health, Inc. is a precision oncology company headquartered in Redwood City, California, specializing in liquid biopsy tests for cancer diagnosis and treatment. The company provides a range of blood tests, including Guardant360, which measures various cancer-related genes for advanced stage cancer treatment selection, and GuardantOMNI, a broader gene panel that supports immuno-oncology research. Additionally, Guardant Health offers LUNAR-1 for detecting minimal residual disease and recurrence in cancer survivors, along with the development of LUNAR-2 for early cancer detection in high-risk individuals. The company also provides development services such as companion diagnostic development and clinical trial support to biopharmaceutical firms and medical institutions. Founded in 2011, Guardant Health is recognized for its innovative approach to addressing unmet needs in oncology through advanced technology and analytics.
Catalia Health
Seed Round in 2017
Catalia Health Inc. is a San Francisco-based company that develops a cloud-based patient care management platform aimed at enhancing healthcare delivery. Established in 2014, the company integrates artificial intelligence, psychology, and medicine to improve patient engagement and support. Its platform provides healthcare providers with real-time data on patient progress and challenges, facilitating effective communication through mobile apps, web interfaces, and an interactive robotic coach. By delivering tailored conversations to patients, Catalia Health aims to address ongoing healthcare issues, ultimately enabling healthcare professionals to monitor adherence to treatment and improve overall patient outcomes.
NMLStream
Seed Round in 2017
NMLStream specializes in artificial intelligence solutions for information technology management. The company has developed decision-making software that connects performance monitoring with automated actions. This software leverages AI to automate and predict system behaviors, making it applicable in cloud, on-premises, or hybrid environments. By generating a unified digital language for system behaviors, NMLStream's technology facilitates collaboration across various IT silos. This capability allows businesses to optimize performance and enhance application uptime, ultimately improving overall operational efficiency.
Clear Labs
Series B in 2016
Clear Labs, Inc. is a food analytics company based in Menlo Park, California, founded in 2013. The company specializes in providing a comprehensive analytics platform that analyzes the molecular contents of food and ingredients. Its offerings include Clear Dx™ and Clear Safety™, which utilize next-generation sequencing and data analytics for food safety testing and infectious disease surveillance. Clear Labs serves food manufacturers, suppliers, and retailers by ensuring transparency throughout the supply chain and testing products for various factors such as authenticity, contamination, allergens, and nutritional content. The platform delivers actionable insights that enhance safety and operational efficiency while supporting public health initiatives. Through its integrated genomics system, Clear Labs aims to simplify complex diagnostics across clinical and applied markets, making genomic insights accessible to labs, hospitals, and businesses.
Pymetrics
Series A in 2016
Pymetrics, Inc. is a company that specializes in developing neuroscience-based assessment and prediction technology aimed at transforming the recruitment, retention, and development of employees. Founded in 2013 and headquartered in New York City, Pymetrics utilizes a combination of neuroscience and machine learning to create a talent matching platform. This platform collects behavioral data from successful professionals across various roles to identify key traits that distinguish top performers from the general population. By offering cognitive and emotional assessment solutions, along with a personalized recommendation engine, Pymetrics enhances the effectiveness and accuracy of the hiring process, while promoting unbiased recruitment practices.
PatternEx
Series A in 2016
PatternEx, Inc. develops artificial intelligence software aimed at identifying malicious user intent and enhancing cybersecurity measures. Founded in 2013 and based in San Jose, California, the company offers a platform that enables real-time prediction and prevention of cyber-attacks across enterprises. By distinguishing between normal and malicious behavior, PatternEx improves attack detection accuracy and reduces false positives, allowing analysts to concentrate on significant alerts. The Virtual Analyst Platform processes log data from various sources, converting it into actionable behaviors, while AI Pipelines facilitate data analysis. The platform's AutoCorrelate feature significantly accelerates threat investigation, reducing the time needed by twenty times. Additionally, custom analytics tools empower users to conduct detailed analyses or extract insights from raw log data, combining artificial intelligence with human expertise to enhance information security.
Lumiata
Series B in 2016
Lumiata Inc. specializes in predictive health analytics tailored for risk-bearing organizations, including hospital networks and insurance carriers. Founded in 2013 and based in San Mateo, California, the company has developed a medical graph that organizes and analyzes diverse healthcare data, enabling real-time predictive analytics. Its flagship product, The Lumiata Risk Matrix, provides personalized predictions regarding individual health changes, supported by a chain of medical reasoning. By leveraging over 120 million patient records and proprietary clinical knowledge, Lumiata's machine learning tools empower healthcare providers and payers to enhance decision-making, manage costs, and improve patient care. The company serves a range of clients, including payers, population health organizations, and digital health companies, facilitating applications in underwriting and care management while prioritizing member privacy.
Olive
Series C in 2016
Olive deploys the AI workforce built specifically for healthcare, delivering hospitals and health systems increased revenue, reduced costs, and increased capacity. Olive automates repetitive, high-volume tasks and workflows, monitoring their performance, identifying improvements, and finding opportunities for new work. Olive gives power back to providers through her ever-growing, unparalleled intelligence made up of shared memories, collective wisdom, and global awareness, learning like a network so hospitals never have to solve the same problem twice. Olive was founded in 2012 and is headquartered in Columbus, Ohio.
Xcalar
Venture Round in 2016
Xcalar, Inc., founded in 2013 and based in San Jose, California, specializes in data infrastructure services through its innovative analytics platform. This platform facilitates the Fundamental Discovery of significant insights directly from petabytes of raw data, enabling businesses to uncover information that would otherwise remain hidden. Xcalar's technology features a relational scale-out compute architecture that enhances the accessibility and management of big data, streamlining the analysis process. Notably, it employs a patent-pending True Data In Place technology that eliminates the need for data preparation or shuffling, allowing for immediate analysis without data movement. This approach results in significantly faster time-to-insight, making Xcalar's solutions highly efficient for organizations dealing with complex datasets.
Guardant Health
Series D in 2016
Guardant Health, Inc. is a precision oncology company headquartered in Redwood City, California, specializing in liquid biopsy tests for cancer diagnosis and treatment. The company provides a range of blood tests, including Guardant360, which measures various cancer-related genes for advanced stage cancer treatment selection, and GuardantOMNI, a broader gene panel that supports immuno-oncology research. Additionally, Guardant Health offers LUNAR-1 for detecting minimal residual disease and recurrence in cancer survivors, along with the development of LUNAR-2 for early cancer detection in high-risk individuals. The company also provides development services such as companion diagnostic development and clinical trial support to biopharmaceutical firms and medical institutions. Founded in 2011, Guardant Health is recognized for its innovative approach to addressing unmet needs in oncology through advanced technology and analytics.
CrowdMed
Seed Round in 2015
CrowdMed, Inc. operates an online platform that utilizes prediction market technology to assist patients in diagnosing complex medical conditions. Founded in 2012 and based in San Francisco, CrowdMed connects patients with a network of medical detectives, including licensed physicians, medical students, and other healthcare professionals, to collaboratively solve challenging medical cases. By leveraging the collective intelligence of thousands of contributors, the platform provides patients with insightful diagnostic suggestions for their unresolved symptoms. This approach not only aims to expedite the diagnostic process for individuals who have struggled with chronic health issues but also seeks to reduce healthcare costs while maintaining quality care. CrowdMed's innovative model positions it as a trusted resource for patients seeking clarity and solutions in their healthcare journeys.
Clear Labs
Series A in 2015
Clear Labs, Inc. is a food analytics company based in Menlo Park, California, founded in 2013. The company specializes in providing a comprehensive analytics platform that analyzes the molecular contents of food and ingredients. Its offerings include Clear Dx™ and Clear Safety™, which utilize next-generation sequencing and data analytics for food safety testing and infectious disease surveillance. Clear Labs serves food manufacturers, suppliers, and retailers by ensuring transparency throughout the supply chain and testing products for various factors such as authenticity, contamination, allergens, and nutritional content. The platform delivers actionable insights that enhance safety and operational efficiency while supporting public health initiatives. Through its integrated genomics system, Clear Labs aims to simplify complex diagnostics across clinical and applied markets, making genomic insights accessible to labs, hospitals, and businesses.
Catalia Health
Seed Round in 2015
Catalia Health Inc. is a San Francisco-based company that develops a cloud-based patient care management platform aimed at enhancing healthcare delivery. Established in 2014, the company integrates artificial intelligence, psychology, and medicine to improve patient engagement and support. Its platform provides healthcare providers with real-time data on patient progress and challenges, facilitating effective communication through mobile apps, web interfaces, and an interactive robotic coach. By delivering tailored conversations to patients, Catalia Health aims to address ongoing healthcare issues, ultimately enabling healthcare professionals to monitor adherence to treatment and improve overall patient outcomes.
Olive
Series B in 2015
Olive deploys the AI workforce built specifically for healthcare, delivering hospitals and health systems increased revenue, reduced costs, and increased capacity. Olive automates repetitive, high-volume tasks and workflows, monitoring their performance, identifying improvements, and finding opportunities for new work. Olive gives power back to providers through her ever-growing, unparalleled intelligence made up of shared memories, collective wisdom, and global awareness, learning like a network so hospitals never have to solve the same problem twice. Olive was founded in 2012 and is headquartered in Columbus, Ohio.
LiftIgniter
Seed Round in 2015
LiftIgniter is a machine learning personalization company based in San Francisco, California, that offers a predictive recommendation platform designed to enhance user engagement and conversion rates. By utilizing data science, LiftIgniter's technology analyzes user interactions in real time, allowing businesses to tailor their websites and applications to better meet customer needs. This personalization engine interprets interest signals from users, facilitating optimized communication and improved sales outcomes. LiftIgniter aims to create intelligent and dynamic experiences across various customer touchpoints, helping businesses connect more effectively with their audiences.
Metamarkets Group
Series C in 2015
Metamarkets is an interactive analytics platform designed for the programmatic advertising sector. Founded in 2010 and headquartered in San Francisco, California, the company provides users with real-time analysis of media marketplaces, empowering both buyers and sellers to enhance their business performance. Metamarkets' platform facilitates ad hoc data navigation and visualization, enabling marketers to gain insights quickly and effectively. Among its clientele are notable companies in the digital advertising space, such as Twitter, AOL, and Rubicon Project. The platform emphasizes security through SSL-encrypted data transfers and offers self-service permissions, ensuring that users can access and manage their data efficiently.
Guardant Health
Series C in 2015
Guardant Health, Inc. is a precision oncology company headquartered in Redwood City, California, specializing in liquid biopsy tests for cancer diagnosis and treatment. The company provides a range of blood tests, including Guardant360, which measures various cancer-related genes for advanced stage cancer treatment selection, and GuardantOMNI, a broader gene panel that supports immuno-oncology research. Additionally, Guardant Health offers LUNAR-1 for detecting minimal residual disease and recurrence in cancer survivors, along with the development of LUNAR-2 for early cancer detection in high-risk individuals. The company also provides development services such as companion diagnostic development and clinical trial support to biopharmaceutical firms and medical institutions. Founded in 2011, Guardant Health is recognized for its innovative approach to addressing unmet needs in oncology through advanced technology and analytics.
DB CyberTech
Series B in 2014
DB CyberTech specializes in developing predictive data loss prevention technologies that safeguard business data through advanced security measures. The company employs deep protocol extraction, machine learning, and behavioral analysis to non-intrusively assess database infrastructures, allowing for the identification of insider threats and potential database attacks. Its solutions provide clients with comprehensive insights into database activities and application interactions, enhancing situational awareness and security posture. DB CyberTech serves a diverse clientele, including financial institutions, healthcare providers, manufacturers, and government entities. Founded in 2009 and headquartered in San Diego, California, the company was previously known as DB Networks before rebranding in May 2018.
Quantopian
Series B in 2014
Quantopian, Inc. operates an online platform designed for the development and testing of quantitative trading algorithms. Founded in 2011 and based in Boston, Massachusetts, the platform offers tools and infrastructure that allow users to learn about quantitative finance, engage in community discussions, and explore algorithms shared by other members. Users can create and backtest their algorithms, review performance results and risk metrics, and trade their strategies. The company boasts a community of approximately 195,000 quants who collaborate and share insights. Additionally, select algorithm authors can license their algorithms to Quantopian, earning compensation based on performance. The firm provides capital, data, and resources to support its community in researching, coding, and executing algorithmic investing strategies.
Tule
Seed Round in 2014
Tule specializes in automated irrigation management solutions, leveraging advanced technology developed in partnership with UC Davis to deliver precise measurements of actual evapotranspiration. Its innovative sensor system monitors water usage over a 1 to 10 acre area, offering comprehensive data that informs irrigation decisions daily. The Tule dashboard provides actionable insights, including weekly forecasts of atmospheric demand, allowing farmers to plan their irrigation schedules effectively. Key features include continuous monitoring of evapotranspiration, tracking of field-level water stress, and the ability to compare irrigation performance across different fields. This enables farmers to optimize water usage, ensure crops receive adequate hydration, and ultimately enhance agricultural productivity.
Guardant Health
Series B in 2014
Guardant Health, Inc. is a precision oncology company headquartered in Redwood City, California, specializing in liquid biopsy tests for cancer diagnosis and treatment. The company provides a range of blood tests, including Guardant360, which measures various cancer-related genes for advanced stage cancer treatment selection, and GuardantOMNI, a broader gene panel that supports immuno-oncology research. Additionally, Guardant Health offers LUNAR-1 for detecting minimal residual disease and recurrence in cancer survivors, along with the development of LUNAR-2 for early cancer detection in high-risk individuals. The company also provides development services such as companion diagnostic development and clinical trial support to biopharmaceutical firms and medical institutions. Founded in 2011, Guardant Health is recognized for its innovative approach to addressing unmet needs in oncology through advanced technology and analytics.
ClearStory Data
Series B in 2014
ClearStory Data Inc. is a provider of data analytics solutions aimed at enhancing business intelligence across various industries, including consumer packaged goods, healthcare, and financial services. Founded in 2011 and headquartered in Menlo Park, California, with an additional office in Chicago, the company specializes in enabling users to easily discover and analyze data from diverse sources, such as relational databases, Hadoop, and third-party data providers. Its platform modernizes data analysis by automating complex tasks like data harmonization and facilitating interactive analysis, allowing organizations to combine corporate and external data for timely insights. This capability empowers business users to make informed decisions quickly, fostering collaboration among distributed teams. ClearStory Data operates as a subsidiary of Alteryx, Inc. as of April 2019.
Lumiata
Series A in 2014
Lumiata Inc. specializes in predictive health analytics tailored for risk-bearing organizations, including hospital networks and insurance carriers. Founded in 2013 and based in San Mateo, California, the company has developed a medical graph that organizes and analyzes diverse healthcare data, enabling real-time predictive analytics. Its flagship product, The Lumiata Risk Matrix, provides personalized predictions regarding individual health changes, supported by a chain of medical reasoning. By leveraging over 120 million patient records and proprietary clinical knowledge, Lumiata's machine learning tools empower healthcare providers and payers to enhance decision-making, manage costs, and improve patient care. The company serves a range of clients, including payers, population health organizations, and digital health companies, facilitating applications in underwriting and care management while prioritizing member privacy.
Kyron
Seed Round in 2013
Kyron, Inc. is a company based in Palo Alto, California, that specializes in analyzing medical records from routine care to produce valuable medical insights. Founded in 2013, Kyron focuses on identifying latent associations between various health conditions, interventions, and outcomes, thereby generating practice-based evidence. Its medical records analysis platform facilitates the discovery of relevant connections among conditions, medications, devices, and procedures. This enables both individuals and healthcare providers to make informed decisions that enhance health and improve healthcare delivery.
Quantopian
Series A in 2013
Quantopian, Inc. operates an online platform designed for the development and testing of quantitative trading algorithms. Founded in 2011 and based in Boston, Massachusetts, the platform offers tools and infrastructure that allow users to learn about quantitative finance, engage in community discussions, and explore algorithms shared by other members. Users can create and backtest their algorithms, review performance results and risk metrics, and trade their strategies. The company boasts a community of approximately 195,000 quants who collaborate and share insights. Additionally, select algorithm authors can license their algorithms to Quantopian, earning compensation based on performance. The firm provides capital, data, and resources to support its community in researching, coding, and executing algorithmic investing strategies.
Pymetrics
Seed Round in 2013
Pymetrics, Inc. is a company that specializes in developing neuroscience-based assessment and prediction technology aimed at transforming the recruitment, retention, and development of employees. Founded in 2013 and headquartered in New York City, Pymetrics utilizes a combination of neuroscience and machine learning to create a talent matching platform. This platform collects behavioral data from successful professionals across various roles to identify key traits that distinguish top performers from the general population. By offering cognitive and emotional assessment solutions, along with a personalized recommendation engine, Pymetrics enhances the effectiveness and accuracy of the hiring process, while promoting unbiased recruitment practices.
CrowdMed
Seed Round in 2013
CrowdMed, Inc. operates an online platform that utilizes prediction market technology to assist patients in diagnosing complex medical conditions. Founded in 2012 and based in San Francisco, CrowdMed connects patients with a network of medical detectives, including licensed physicians, medical students, and other healthcare professionals, to collaboratively solve challenging medical cases. By leveraging the collective intelligence of thousands of contributors, the platform provides patients with insightful diagnostic suggestions for their unresolved symptoms. This approach not only aims to expedite the diagnostic process for individuals who have struggled with chronic health issues but also seeks to reduce healthcare costs while maintaining quality care. CrowdMed's innovative model positions it as a trusted resource for patients seeking clarity and solutions in their healthcare journeys.
Evolv
Series D in 2013
Evolv is a big data company that helps solve workforce performance issues for the C-suite by utilizing a configurable cloud services platform. Evolv's patent-pending technology platform unifies and supplements existing data from current systems, then utilizes that dataset to identify fact-based workforce insights that drive measurable ROI. By using objective, data-driven methodology, Evolv helps companies uncover the core reasons behind workforce performance, enabling executives to make better operational business decisions that generally result in tens of millions of dollars in measureable value per year.
DB CyberTech
Series B in 2013
DB CyberTech specializes in developing predictive data loss prevention technologies that safeguard business data through advanced security measures. The company employs deep protocol extraction, machine learning, and behavioral analysis to non-intrusively assess database infrastructures, allowing for the identification of insider threats and potential database attacks. Its solutions provide clients with comprehensive insights into database activities and application interactions, enhancing situational awareness and security posture. DB CyberTech serves a diverse clientele, including financial institutions, healthcare providers, manufacturers, and government entities. Founded in 2009 and headquartered in San Diego, California, the company was previously known as DB Networks before rebranding in May 2018.
tenXer
Series B in 2012
tenXer is a company focused on enhancing personal productivity through its innovative platform that allows employees to analyze their daily work habits. Founded by Jeff Ma, who was inspired by his experiences in the human capital management industry, tenXer targets individual workers rather than upper management. The platform employs a proprietary, data-driven approach to help employees gain insights into their performance and work habits. By collecting data from various cloud-based services where users already operate, tenXer presents this information in an engaging format. Additionally, the platform integrates social and game-like motivational systems, encouraging users to improve productivity and foster intrinsic motivation. Through this comprehensive approach, tenXer aims to redefine how individuals understand and enhance their work performance.
Metamarkets Group
Series B in 2012
Metamarkets is an interactive analytics platform designed for the programmatic advertising sector. Founded in 2010 and headquartered in San Francisco, California, the company provides users with real-time analysis of media marketplaces, empowering both buyers and sellers to enhance their business performance. Metamarkets' platform facilitates ad hoc data navigation and visualization, enabling marketers to gain insights quickly and effectively. Among its clientele are notable companies in the digital advertising space, such as Twitter, AOL, and Rubicon Project. The platform emphasizes security through SSL-encrypted data transfers and offers self-service permissions, ensuring that users can access and manage their data efficiently.
ClearStory Data
Venture Round in 2012
ClearStory Data Inc. is a provider of data analytics solutions aimed at enhancing business intelligence across various industries, including consumer packaged goods, healthcare, and financial services. Founded in 2011 and headquartered in Menlo Park, California, with an additional office in Chicago, the company specializes in enabling users to easily discover and analyze data from diverse sources, such as relational databases, Hadoop, and third-party data providers. Its platform modernizes data analysis by automating complex tasks like data harmonization and facilitating interactive analysis, allowing organizations to combine corporate and external data for timely insights. This capability empowers business users to make informed decisions quickly, fostering collaboration among distributed teams. ClearStory Data operates as a subsidiary of Alteryx, Inc. as of April 2019.
Incredible Labs
Seed Round in 2011
Incredible Labs, Inc., founded in 2011 and based in San Francisco, California, develops artificial intelligence software, notably a mobile anticipatory assistant called Donna. This innovative personal assistant is designed to predict and fulfill individual user needs, enhancing personal productivity and convenience.
Kaggle
Series A in 2011
Kaggle Inc. is a prominent platform that facilitates data prediction competitions, allowing organizations to submit their datasets for analysis by a global community of data scientists. Established in 2010 and headquartered in San Francisco, Kaggle serves a diverse range of sectors, including pharmaceuticals, financial services, energy, information technology, and retail. The platform not only hosts competitions but also provides access to datasets, models, and coding resources, enabling users to collaboratively execute and refine their data science projects. Additionally, Kaggle Prospect, one of its offerings, assists companies and government entities in transforming raw data into actionable insights. As a subsidiary of Google, Kaggle continues to foster innovation in data science, positioning itself as a vital resource for professionals seeking to address complex challenges across various industries.
Evolv
Series C in 2011
Evolv is a big data company that helps solve workforce performance issues for the C-suite by utilizing a configurable cloud services platform. Evolv's patent-pending technology platform unifies and supplements existing data from current systems, then utilizes that dataset to identify fact-based workforce insights that drive measurable ROI. By using objective, data-driven methodology, Evolv helps companies uncover the core reasons behind workforce performance, enabling executives to make better operational business decisions that generally result in tens of millions of dollars in measureable value per year.
Hunch
Series B in 2010
Hunch is a consumer web application that is building the "taste graph" of the internet, mapping every person on the internet to every entity on the internet and their affinity for that entity. An entity could be a web site, a cookbook, a hotel room, a celebrity, a restaurant, etc. Hunch creates a taste profile by asking them a series of questions which range from serious to profound and subsequently can make recommendations personalized to that user, which live in "topics". Topics vary widely, from entertaining subjects like 'Which superhero would you be' to more conventional questions like 'Should I Switch to A Mac?' The system then uses the answers to these questions to offer the user a suggested solution, a "hunch" of what the user would like.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.